In the latest episode of The A100 Podcast, we sit down with Carter Alleman, the Director of Government Affairs & Science Policy at the American Society for Pharmacology and Experimental Therapeutics (ASPET). Show co-hosts, OnWrd & UpWrd’s Meghan Henning and Keaveny Hewitt dive into the intersection of advocacy and storytelling with Carter, exploring its profound impact on scientific progress.
ASPET, a renowned association with approximately 6,000 dedicated members, occupies a prominent position in research. Their primary focus centers on unraveling the intricate interactions between drug compounds and the human body. Their work serves as the vital first steps in pioneering treatments and drugs destined for the market, as well as contributing to the development of life-changing medications.
However, despite their pivotal role in healthcare advancements, ASPET continually grapples with a recurring challenge – securing funding for their work. Often heralded as the true incubators of discovery in the United States, they heavily depend on funding from sources such as the National Institutes of Health (NIH) and the National Science Foundation. Unfortunately, their funding is all too frequently subject to budget cuts during the appropriations process, posing a substantial obstacle to their mission.
As a way to combat that, Carter shares that ASPET actively engages its members in the advocacy process. He acknowledges that scientists may not inherently gravitate toward advocacy, given its perceived political nature. Therefore, ASPET underscores the power of storytelling as a formidable tool in their advocacy efforts. 
Carter talks through one of their initiatives, the Washington Fellows program, which is an innovative program that escorts 10 early-career scientists to Capitol Hill, where they share their research and forge direct connections with policymakers. These personal interactions bridge the gap between science and policy. This program is an integral part of a broader strategy aimed at preparing members to become active participants in shaping policy discussions, rather than passive observers.
ASPET is keenly aware that effective advocacy extends beyond mere congressional testimony; it hinges on active engagement with elected officials who share common interests and concerns.
In an era where science has become increasingly entwined with politics, ASPET acknowledges the inseparable nature of these two realms. While government funding and support are indispensable for scientific progress, they also recognize the necessity of navigating the intricate political landscape while steadfastly remaining committed to their overarching mission of advancing public health.
To gain further insights into the ever-evolving relationship between science, advocacy, and policy, be sure to tune in to this episode of The A100 podcast. 
Subscribe today so you never miss out on future episodes. 
Follow along for best practices, top trends, helpful ideas and smart strategies and tactics that work in the world of associations. 
LinkedIn: /company/the-association-100